Sofosbuvir and velpatasvir with or without voxilaprevir in direct ‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

ConclusionsThe pan‐genotypic regimens with SOF/VEL with or without VOX not only have excellent efficacy and safety, but also significantly positively impact patients’ experience both during treatment and after achieving sustained virologic response in DAA‐naïve patients with HCV.

Source: Alimentary Pharmacology and Therapeutics - November 27, 2017 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, I. M. Jacobson, T. Asselah, E. J. Gane, E. Lawitz, G. R. Foster, S. K. Roberts, A. J. Thompson, B. E. Willems, T. M. Welzel, B. Pearlman, I. Younossi, A. Racila, L. Henry Tags: ORIGINAL ARTICLE Source Type: research